Lowering hematocrit while on testosterone replacement therapy (TRT) starts with confirming the result and reviewing your treatment with the clinician who manages your TRT. According to the American Urological Association (AUA), a hematocrit of 54% or higher warrants intervention.1 Options your prescriber may recommend include reducing testosterone exposure, adjusting the dosing schedule or delivery method, treating sleep apnea or smoking, and arranging a hematology review when appropriate. Do not stop or change TRT on your own, and do not use blood donation as an unsupervised treatment.
Why TRT Raises Hematocrit and Hemoglobin
Hematocrit is the percentage of your blood volume made up of red blood cells. Hemoglobin is the oxygen-carrying protein inside those cells. Your laboratory may abbreviate them as Hct and Hb.
Testosterone stimulates erythropoiesis, which is the production of red blood cells. More red blood cells can raise both hematocrit and hemoglobin.
Testosterone also suppresses hepcidin, a hormone that controls how much iron enters circulation. Lower hepcidin increases iron availability for hemoglobin and red blood cell production.2 Testosterone can also increase erythropoietin, a hormone that signals the bone marrow to produce red blood cells.3
This response does not affect every man equally. Testosterone formulation, blood concentrations, dose exposure, smoking, sleep apnea, and other sources of low oxygen can influence the result.1,4
The AUA notes that hemoglobin and hematocrit generally rise during the first six months of testosterone therapy and then tend to plateau.1 A rising value still requires review. Waiting for a plateau is not an appropriate response once hematocrit reaches an intervention threshold.
Hematocrit Thresholds During TRT
Guidelines use different thresholds for defining an elevated result and directing treatment. A value above 52% meets the AUA’s general definition of polycythemia, while a value of 54% or higher warrants intervention during TRT.1
The Endocrine Society uses a separate treatment threshold. Its guideline advises stopping testosterone when hematocrit is above 54%, evaluating for hypoxia and sleep apnea, and restarting at a reduced dose once hematocrit reaches a safe level.5
| Clinical Situation | Published Threshold | Recommended Action |
|---|---|---|
| Before starting TRT | Hematocrit above 50% | The AUA says clinicians should consider withholding TRT until the cause is explained.1 |
| General definition of polycythemia | Hematocrit above 52% | The AUA generally defines polycythemia, also called erythrocytosis, at this level.1 The result calls for clinical review, though it is below the AUA intervention threshold. |
| During TRT | Hematocrit of 54% or higher | The AUA says this warrants intervention. High on-treatment testosterone supports dose adjustment as first-line management.1 |
| During TRT | Hematocrit above 54% | The Endocrine Society advises holding testosterone, evaluating for hypoxia and sleep apnea, and restarting at a reduced dose after hematocrit reaches a safe level.5 |
These thresholds guide treatment decisions. They do not show whether you currently have a blood clot or predict your individual outcome from one test.
The degree of clotting risk caused specifically by TRT-related erythrocytosis remains uncertain. A 2024 review found limited evidence for routine phlebotomy and raised concerns about iron depletion from repeated blood removal.6 Your symptoms, treatment exposure, and related lab results all affect the management plan.
Prescriber-Directed Ways to Bring Hematocrit Down
Lowering hematocrit usually requires a prescriber to address testosterone exposure and any contributing causes. Hydration can correct a concentrated sample caused by dehydration, but it does not remove excess red blood cells.
Confirmation With Repeat Testing
A repeat complete blood count can confirm whether hematocrit remains elevated. Your clinician can interpret that result alongside hemoglobin, symptoms, testosterone exposure, and previous results.
On-treatment testosterone levels can change the next step. The AUA recommends dose adjustment first when hematocrit is elevated and on-treatment testosterone is high.1 Elevated hematocrit with low or normal total and free testosterone calls for hematology evaluation and possible coordination of phlebotomy.1
A testosterone blood test and related hormone panel can help your prescriber assess testosterone exposure. One hematocrit result is a data point. Its relationship to hemoglobin, testosterone levels, and prior results creates the clinical pattern.
Prescriber-Led Dose Adjustment
Reducing testosterone exposure can lower the stimulus for red blood cell production. The AUA identifies dose adjustment as first-line management when hematocrit is elevated and on-treatment testosterone is high.1
The dose decision belongs to your prescriber. Changing or stopping TRT without medical direction can disrupt symptom control and make follow-up results harder to interpret.
Injection Frequency and Testosterone Peaks
Injection timing affects the peaks and troughs of testosterone in the blood. Different testosterone formulations produce different concentration patterns.7
A prescriber may consider changing injection frequency when high peaks are contributing to excess exposure. Evidence does not establish that splitting injections reliably lowers hematocrit for every patient. Frequency changes also alter how the prescription works, so they require clinical direction.
Alternative Testosterone Delivery Methods
Testosterone formulations differ in their association with erythrocytosis. A clinical review found the highest incidence with short-acting injectable testosterone compared with other formulations.4
Switching to a delivery method with steadier blood concentrations may be considered when hematocrit continues to rise. The choice depends on symptoms, testosterone levels, tolerance, and treatment goals. Your prescriber should make that change and arrange follow-up testing.
Sleep Apnea, Smoking, and Other Contributors
Untreated sources of low oxygen can contribute to elevated hematocrit. The AUA lists obstructive sleep apnea and tobacco use among causes of acquired erythrocytosis.1
Treating sleep apnea or stopping smoking may reduce an additional stimulus for red blood cell production. These steps also help your clinician determine how much of the elevation is related to TRT.
Living at high altitude and chronic lung disease are also listed by the AUA as potential contributors.1 A persistent elevation may therefore require evaluation beyond the testosterone prescription.
Therapeutic Phlebotomy Under Clinical Direction
Therapeutic phlebotomy is the planned removal of blood under medical direction. It can reduce circulating red blood cells, but repeated procedures may deplete iron stores.
The AUA recommends hematology referral when hematocrit is elevated despite low or normal on-treatment total and free testosterone. A hematologist may then evaluate the cause and coordinate phlebotomy when appropriate.1
Routine phlebotomy for every elevated result is not well supported. The 2024 review by Bond and colleagues questions whether the practice is justified without better evidence and discusses the effects of iron depletion from repeated treatment.6
Blood Donation Outside Medical Treatment
Voluntary blood donation is not a substitute for a treatment plan. Donation centers follow their own eligibility standards and do not manage TRT-related erythrocytosis.
The American Red Cross eligibility requirements determine whether a person may donate.8 Eligibility does not establish that donation is medically appropriate for your elevated hematocrit.
If blood removal is being considered, your prescriber should clarify whether therapeutic phlebotomy is appropriate and how iron status will be followed. Do not establish your own recurring donation schedule to manage a lab result.
Hydration and Concentrated Results
Drinking water can affect hematocrit when dehydration has reduced the liquid portion of the blood. Restoring normal hydration may lower a value that was temporarily concentrated.
Water does not reduce an increased red blood cell mass. A persistent elevation after normal hydration requires clinical review. There is no drink, food, or supplement that reliably reverses testosterone-induced erythrocytosis overnight.
Hematocrit Monitoring During TRT
The Endocrine Society recommends measuring hematocrit at baseline, three to six months after starting testosterone, and annually after that.5 More frequent testing may be needed after an elevated result or a treatment change, with timing set by the prescribing clinician.
The AUA recommends baseline hemoglobin and hematocrit before testosterone therapy.1 Its guideline also says patients should be informed about the increased risk of polycythemia before treatment begins.1
General prescribing and follow-up at Opt Health are described in the testosterone replacement therapy protocol. Your individual hematocrit plan should remain tied to your current blood count and testosterone exposure.
Urgent Symptoms and Routine Follow-Up
A high hematocrit result without acute symptoms usually calls for prompt contact with your prescriber and a plan for confirmation or treatment. A laboratory threshold alone does not diagnose a blood clot.
Seek urgent medical care for possible clot symptoms such as sudden trouble breathing, chest pain, coughing up blood, fainting, or swelling and pain in one limb. MedlinePlus identifies these among the possible symptoms of blood clots.9
Do not wait for a routine TRT visit when those symptoms are present. Emergency evaluation addresses the symptoms first, while the hematocrit and TRT plan can be reviewed afterward.
Frequently asked questions
Lowering hematocrit starts with confirming the result and identifying its cause. During TRT, prescriber-directed options can include reducing testosterone exposure, changing the delivery method, addressing sleep apnea or smoking, and arranging hematology evaluation.
Therapeutic phlebotomy may be considered under clinical direction. Blood donation should not be used as unsupervised treatment. Your prescriber should compare hematocrit with hemoglobin, on-treatment testosterone levels, symptoms, and previous results before choosing an option.
Drinking water can lower a hematocrit value when dehydration made the blood sample more concentrated. Normal hydration does not remove excess red blood cells or reverse testosterone-driven erythrocytosis.
If a repeat result remains elevated after normal fluid intake, the next step is prescriber review. Do not rely on excessive water intake to manage a persistent elevation.
A high hematocrit needs review, but one result does not determine your personal risk. The AUA generally defines polycythemia as hematocrit above 52% and says hematocrit of 54% or higher during TRT warrants intervention.1
Contact your prescriber promptly when the result reaches an action threshold. Seek urgent care for sudden chest pain, trouble breathing, coughing up blood, fainting, or one-sided limb swelling and pain.9
There is no single timeline for lowering hematocrit. A concentration change caused by dehydration can improve faster than an increase in red blood cell mass.
The AUA notes that hemoglobin and hematocrit generally rise during the first six months of TRT before tending to plateau.1 That statement does not establish how quickly an elevated value will fall after treatment changes. Your prescriber should choose the follow-up date based on the result and the intervention used.
References
- American Urological Association. Testosterone Deficiency Guideline.
- Bachman E, Feng R, Travison T, et al. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. J Clin Endocrinol Metab. 2010;95(10):4743-4747.
- Bachman E, Travison TG, Basaria S, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin. J Gerontol A Biol Sci Med Sci. 2014;69(6):725-735.
- Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis following testosterone therapy. Sex Med Rev. 2018;6(1):77-85.
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
- Bond P, Verdegaal T, Smit DL. Testosterone therapy-induced erythrocytosis: can phlebotomy be justified? Endocr Connect. 2024;13(10).
- Pastuszak AW, Gittelman M, Tursi JP, et al. Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age. Andrology. 2022;10(2):209-222.
- American Red Cross. Blood donation eligibility requirements.
- National Library of Medicine. Blood clots. MedlinePlus.
Physician-Led TRT Follow-Up
Opt Health membership pairs lab testing with a physician who reviews your results, manages treatment, and adjusts the plan as your numbers change. Become an Opt Health member to discuss physician-led hormone management.
This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.
Start Today
Your health, your terms. Discover how personalized care can transform not just the way you feel, but how you live.